Gufic Biosciences Limited

Equities

GUFICBIO

INE742B01025

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:48 2024-04-30 am EDT 5-day change 1st Jan Change
326.8 INR +1.29% Intraday chart for Gufic Biosciences Limited +9.72% +3.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Gufic Biosciences Forms New Wholly-Owned Arm in Dubai MT
Gufic Biosciences Limited Incorporates Wholly Owned Subsidiary Company in Dubai CI
Gufic Biosciences Limited Announces Demise of Shrirang Vaidya, Independent Director, Chairman of Audit Committee and Nomination and Remuneration Committee and Member of Risk Management Committee CI
Gufic Biosciences Secures Patent in India MT
Transcript : Gufic Biosciences Limited, Q3 2024 Earnings Call, Feb 16, 2024
Gufic Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Gufic Biosciences Gets New Patent in India MT
Gufic Biosciences Forms New Pharmaceutical Subsidiary MT
Transcript : Gufic Biosciences Limited, Q2 2024 Earnings Call, Nov 17, 2023
Gufic Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection CI
Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited CI
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2023 CI
Gufic Biosciences Limited Approves Incorporation of Wholly Owned Subsidiary in Dubai, UAE CI
Gufic Biosciences Granted Patent for its Invention MT
Gufic Biosciences Gets Nod from Australian, Brazilian Regulators for Parecoxib Sodium Lyophilized Powder MT
Gufic Biosciences Limited Receives Approval of TGA, Australia and the National Health Surveillance Agency, Brazil for Parecoxib 40Mg Injection CI
Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023 CI
Motilal Oswal Financial to Acquire 3% Stake in Gufic Biosciences for INR1 Billion MT
Gufic Biosciences Limited announced that it expects to receive INR 999.9 million in funding from Motilal Oswal Financial Services Limited CI
Transcript : Gufic Biosciences Limited, Q1 2024 Earnings Call, Aug 14, 2023
Gufic Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Gufic Biosciences Limited Receives Approval from NMPA, China for Prilocaine API CI
Gufic Biosciences Limited Receives Approval from the Drug Controller General of India for Both Dalbavancin Api and Formulation CI
Transcript : Gufic Biosciences Limited, Q4 2023 Earnings Call, May 30, 2023
Chart Gufic Biosciences Limited
More charts
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates through the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
More about the company
  1. Stock Market
  2. Equities
  3. GUFICBIO Stock
  4. News Gufic Biosciences Limited
  5. Crisil Affirms BBB+ Rating on Gufic BioSciences' Bank Loans; Raises Outlook to Positive